Erratum

F. Proft¹, J. Kopf², D. Olmes¹, S. Hempel¹, B. Schmidt¹, P. Riederer¹, J. Deckert¹, B. Pfuhlmann¹, A. Reif²*, S. Unterecker¹*

¹ Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Germany
² current position: Department of Psychiatry, Psychosomatics and Psychotherapy, Johann Wolfgang Goethe University Frankfurt, Germany
³ current position: Department of Neurology, Friedrich-Alexander University Erlangen-Nuremberg, Germany
⁴ current position: Städtisches Krankenhaus Dresden Neustadt, Klinik für Psychiatrie und Psychotherapie Weißer Hirsch, Dresden, Germany
* both authors contributed equally to this paper

Pharmacopsychiatry 2014; 47: 245–250

The article “Proft F et al. – SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome – Pharmacopsychiatry 2014; 47: 245–250. http://dx.doi.org/10.1055/s-0034-1390412” has been published containing a misarranged figure. In Fig. 1, displaying the “Distribution (percentage) of good and poor response in relation to low (lAlG/lGlG/slA/slG/ss) and high (lAlA) expressing SLC6A4 genotypes in the investigated sample (ntotal = 56)”, there was a mix-up between the denomination of the x-axis and the legend. Actually on the x-axis SLC6A4-genotypes are given while on the y-axis, respectively in the legend, percentages of good respectively poor response are displayed. We would like to now give the correct figure and apologize for our mistake. The conclusion of the study remains unchanged, carriers of the high expressing SLC6A4-genotype to a higher percentage show a poor treatment response and in the group of low expressing genotype there appears more often good response.

Originally published figure:

Corrected figure (Fig. 1):

Fig. 1 Distribution (percentage) of good and poor response in relation to low- (lAlG/lGlG/slA/slG/ss) and high- (lAlA) expressing SLC6A4 genotypes in the investigated sample (ntotal = 56).